Endoglin as a marker in cervical paragangliomas

Head and Neck

Volumn 32, Issue 6, 2010, Pages 737-743

  Eleno, Nélida ^a   Düwel, Annette ^a   Muñoz, Angel ^b   Paz Bouza, José ^b   López Novoa, Jose Miguel ^a   Lozano, Francisco ^c  

^a Instituto Reina Sofia de Investigacion Nefrologica   (Spain)

^b Hospital Clinico Universitario   (Spain)

^c UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Angiogenesis; Endoglin; Endothelium; Paraganglioma; Vascular endothelial growth factor (VEGF)

Indexed keywords

ENDOGLIN; ENDOGLIN ANTIBODY; HYPOXIA INDUCIBLE FACTOR; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CERVICAL PARAGANGLIOMA; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; ENDOTHELIUM CELL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG RESECTION; PARAGANGLIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TUMOR VASCULARIZATION;

ADULT; AGED; ANTIGENS, CD; BLOTTING, WESTERN; DISEASE PROGRESSION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PARAGANGLIOMA; RECEPTORS, CELL SURFACE; TUMOR MARKERS, BIOLOGICAL; VASCULAR CELL ADHESION MOLECULE-1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77952748426     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21248     Document Type: Article

References (35)

1. Boedeker CC, Ridder GJ, Schipper J. Paragangliomas of the head and neck: diagnosis and treatment. Fam Cancer 2005;4:55-59. (Pubitemid 40754846)
2. Erickson D, Kudva YC, Ebersold MJ, et al. Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients. J Clin Endocrinol Metab 2001;86:5210-5216. (Pubitemid 33070237)
3. Astrom K, Cohen JE, Willett-Brozick JE, Aston CE, Baysal BE. Altitude is a phenotypic modifier in hereditary paraganglioma type 1: evidence for an oxygen-sensing defect. Hum Genet 2003;113:228-237. (Pubitemid 36992281)
4. Prabhakar NR, Jacono FJ. Cellular and molecular mechanisms associated with carotid body adaptations to chronic hypoxia. High Alt Med Biol 2005;6:112-120.
5. Rodríguez-Cuevas S, López-Garza J, Labastida-Almendaro S. Carotid body tumors in inhabitants of altitudes higher than 2000 meters above sea level. Head Neck 1998;20:374-378.
6. Pawlu C, Bausch B, Neumann PH. Mutations of the SDHB and SDHD genes. Fam Cancer 2005;4:49-54.
7. Luna-Ortiz K, Rascon-Ortiz M, Villavicencio-Valencia V, et al. Carotid body tumors: review of a 20-year experience. Oral Oncol 2005;41:56-61. (Pubitemid 39647120)
8. Gougos A, Letarte M. Identification of human endothelial cell antigen with monoclonal antibody 44G4 produced against a pre-B leukemic cell line. J Immunol 1988;141:1925-1933.
9. Adam PJ, Clesham GJ, Weissberg PL. Expression of endoglin mRNA and protein in human vascular smooth muscle cells. Biochem Biophys Res Commun 1998; 247:33-37. (Pubitemid 28412520)
10. Lastres P, Bellon T, Cabañas C, et al. Regulated expression on human macrophages of endoglin, an Arg-Gly-Asp-containing surface antigen. Eur J Immunol 1992;22:393-397.
11. Rodríguez-Barbero A, Obreo J, Eleno N, et al. Endoglin expression in human and rat mesangial cells and its upregulation by TGF-beta1. Biochem Biophys Res Commun 2001;282:142-147. (Pubitemid 32924356)
12. Jerkic M, Rodríguez-Barbero A, Prieto M, et al. Reduced angiogenic responses in adult endoglin heterozygous mice. Cardiovasc Res 2006;69:845-854.
13. Arthur HM, Ure J, Smith AJ, et al. Endoglin, an ancillary TGFbeta receptor, is required for extraembryonic angiogenesis and plays a key role in heart development. Dev Biol 2000;217:42-53.
14. Bourdeau A, Dumont DJ, Letarte M. A murine model of hereditary hemorrhagic telangiectasia. J Clin Invest 1999;104:1343-1351.
15. Li DY, Sorensen LK, Brooke BS, et al. Defective angiogenesis in mice lacking endoglin. Science 1999;284:1534-1537.
16. McAllister KA, Grogg KM, Johnson DW, et al. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 1994;8:345-351.
17. Li C, Hampson IN, Hampson L, Kumar P, Bernabeu C, Kumar S. CD105 antagonizes the inhibitory signaling of transforming growth factor beta1 on human vascular endothelial cells. FASEB J 2000;14:55-64.
18. Burrows FJ, Derbyshire EJ, Tazzari PL, et al. Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin Cancer Res 1995;1:1623-1634.
19. Fonsatti E, Jekunen AP, Kairemo KJ, et al. Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model. Clin Cancer Res 2000;6:2037-2043.
20. Wang JM, Kumar S, Pye D, van Agthoven AJ, Krupinski J, Hunter RD. A monoclonal antibody detects heterogeneity in vascular endothelium of tumors and normal tissues. Int J Cancer 1993;54:363-370.
21. Brieger J, Bedavanija A, Gosepath J, Maurer J, Mann WJ. Vascular endothelial growth factor expression, vascularization and proliferation in paragangliomas. ORL J Otorhinolaryngol Relat Spec 2005;67:119-124. (Pubitemid 40868748)
22. Duff SE, Li C, Garland JM, Kumar S. CD105 is important for angiogenesis: evidence and potential applications. FASEB J 2003;17:984-992.
23. Alejandre-Alcázar MA, Michiels-Corsten M, Vicencio AG, et al. TGF-beta signaling is dynamically regulated during the alveolarization of rodent and human lungs. Dev Dyn 2008;237:259-269.
24. Docherty NG, López-Novoa JM, Arevalo M, et al. Endoglin regulates renal ischaemia-reperfusion injury. Nephrol Dial Transplant 2006;21:2106-2119. (Pubitemid 44295035)
25. Düwel A, Eleno N, Jerkic M, et al. Reduced tumor growth and angiogenesis in endoglin-haploinsufficient mice. Tumour Biol 2007;28:1-8. (Pubitemid 46012460)
26. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
27. Quintanilla M, Ramirez JR, Pérez-Gómez E, et al. Expression of the TGF-beta coreceptor endoglin in epidermal keratinocytes and its dual role in multistage mouse skin carcinogenesis. Oncogene 2003;22:5976-5985. (Pubitemid 37179945)
28. Miller DW, Graulich W, Karges B, et al. Elevated expression of endoglin, a component of the TGF-beta-receptor complex, correlates with proliferation of tumor endothelial cells. Int J Cancer 1999;81:568-572. (Pubitemid 29203054)
29. Jyung RW, LeClair EE, Bernat RA, et al. Expression of angiogenic growth factors in paragangliomas. Laryngoscope 2000;110:161-167. (Pubitemid 30046664)
30. Minhajat R, Mori D, Yamasaki F, Sugita Y, Satoh T, Tokunaga O. Organ-specific endoglin (CD105) expression in the angiogenesis of human cancers. Pathol Int 2006;56:717-723. (Pubitemid 44691157)
31. Semenza GL. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 1999;15:551-578. (Pubitemid 32250386)
32. Li C, Issa R, Kumar P, et al. CD105 prevents apoptosis in hypoxic endothelial cells. J Cell Sci 2003;116(Pt 13): 2677-2685. (Pubitemid 36857221)
33. Sánchez-Elsner T, Botella LM, Velasco B, Langa C, Bernabéu C. Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways. J Biol Chem 2002;277:43799-43808. (Pubitemid 36157800)
34. Gimenez-Roqueplo AP, Favier J, Rustin P, et al. Functional consequences of a SDHB gene mutation in an apparently sporadic pheocromocytoma. J Clin Endocrinol Metab 2002;87:4771-4774. (Pubitemid 35247074)
35. Kontogeorgos G, Scheithauer BW, Kovacs K, Horvath E, Melmed S. Growth factors and cytokines in paragangliomas and pheochromocytomas, with special reference to sustentacular cells. Endocr Pathol 2002;13:197-206. (Pubitemid 36021031)